Lundbeck has announced headline results for Lu AA21004.
To view webcast, please click here.
Financial guidance 2012
The underlying strong trend for 2011 is expected to continue in 2012. However, the company is facing patent expiry for escitalopram in the US in March 2012, which will result in a revenue decline for Lexapro®. Consequently, a drop in earnings is also expected.
For the full year 2012, Lundbeck expects revenue to be DKK 14.5-15.2 billion, profit from operations before depreciation and amortisation (EBITDA) to be DKK 3.0-3.5 billion and profit from operations (EBIT) to be DKK 2.0-2.5 billion.
| 2011 DKKm |
2012 DKKbn |
|
|---|---|---|
| 16,007 | Revenue |
14.5 - 15.2 |
| 4,628 | EBITDA |
3.0 - 3.5 |
| 393 | EBIT |
2.0 - 2.5 |
Floor guidance 2011-2014
In connection with the third quarter results 2010, Lundbeck provided a floor guidance for the period 2011-2014. For more information on the assumptions behind the guidance, please see the related release - Release no 415
| DKKm | 2013e | 2014e |
|---|---|---|
| Revenue | >14 bn | >14 bn |
| SG&A costs | 37-40% | 37-40% |
| R&D costs | approx 20% | approx 20% |
| EBIT | >2 bn | >2 bn |
Lundbeck's historical target achievements 2005-2011
| Revenue | EBIT | |||
|---|---|---|---|---|
| DKKbn | Actual | Target* | Actual | Target* |
| 2011 | 16.0 | 15.3-15.8 | 3.4 | 3.3-3.6 |
| 2010 | 14.8 | 14.6-14.8 | 3.4 | 3.3-3.4 |
| 2009 | 13.7 | 13.1-13.6 | 2.9 | 2.8-3.0 |
| 2008 | 11.3 | 11.0-11.5 | 2.8 | 2.8-2.9 |
| 2007 | 11.0 | - | 2.7 | >2.6 |
| 2006 | 9.2 | - | 1.6 | ~1.6 |
| 2005 | 9.0 | - | 2.2 | ~2.2 |
Disclaimer
Forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations.Factors that may affect future results include interest rate and exchange rate fluctuations, delay or failure of development projects, production problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Lundbeck's products, introduction of competing products, Lundbeck's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof and unexpected growth in expenses. Pursuant to section 107a of the Danish Financial statements Act, listed companies are under an obligation to consider whether they wish to disclose whether material agreements will be affected in the event of a change of control of the company. For reasons of competition, Lundbeck does not wish to disclose this.
Lu AA21004 conference call
